SABCS 2023 | SUCCESS-A trial: ctDNA screening’s potential in early-stage breast cancer recurrence prediction

Wolfgang Janni, MD, PhD, from the University of Ulm, Germany, discusses findings from the Phase III SUCCESS-A (NCT02181101) trial focusing on circulating tumor DNA (ctDNA) in patients with breast cancer two years after chemotherapy. The study involved 311 patients, utilizing the Guardant Reveal test to detect ctDNA through mutations and methylation patterns. The test demonstrated high specificity, exceeding 95%. Patients with positive ctDNA results exhibited a more than tenfold increased risk of later recurrence. Prof. Janni suggests that ctDNA screening could be valuable in identifying patients at high risk for recurrence, providing a potential lead time of more than two years for early intervention. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing, protected by global copyright laws. All rights are reserved.